Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HiJAKing Immunotherapy-Resistant Melanoma for a Cure

The Oncologist(2023)10.1093/oncolo/oyac270Source: DataRank Database

HiJAKing Immunotherapy-Resistant Melanoma for a Cure is a research paper published in The Oncologist (2023). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.00)OA: goldTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Hongxing Shen ORCID,Oluwagbemiga A. Ojo ORCID,James A. Bonner ORCID,Lewis Z. Shi ORCID

Live enrichment

PubMed:36640142 PMC:PMC10020808 OpenAlex:https://openalex.org/W4316116067

American Cancer Society

Grant: 91-022-19

Cancer Research Institute

Grant: CRI4342

Congressionally Directed Medical Research Programs

Grant: ME210108

NIH

Grant: 1R21CA230475-01A1

Targeting metabolic checkpoints in the tumor microenvironment to boost efficacy of anti-CTLA-4

NIH

Grant: 1R21CA259721-01A1

Overcoming Tumor-Intrinsic Therapeutic Resistance to Immunotherapies

NCI NIH HHS

Grant: R01 CA279849

NCI NIH HHS

Grant: R21 CA259721

NCI NIH HHS

Grant: R21 CA230475

Siemens Healthineers

FWCI

0.00

Citation Percentile

0.0%

goldLicense: cc-by

journalhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyac270/48713570/oyac270.pdf

publisherhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyac270/48713570/oyac270.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/28/3/196/49806780/oyac270.pdf

journalhttp://dx.doi.org/10.1093/oncolo/oyac270

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36640142

Fields of Study

Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses0301 basic medicine0303 health sciences03 medical and health sciencesHumansImmunotherapyMelanomaImmune Checkpoint InhibitorsDrug Resistance, Neoplasm

MeSH Terms

Immune Checkpoint InhibitorsHumansImmunotherapyMelanomaDrug Resistance, Neoplasm

Keywords

MelanomaImmunotherapyMedicineResistance (ecology)Metastatic melanomaImmune checkpointImmune systemImmunologyCancer researchBiologyImmune Checkpoint BlockersJak Inhibition (Jaki)Drug Resistance, NeoplasmCommentariesHumansImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being

HiJAKing Immunotherapy-Resistant Melanoma for a Cure

FAIR Checklist

Authors (4)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)